|
|
|
NEW YORK, Nov. 18 /PRNewswire/ -- These and other market data and trends are presented in "Antibiotics: Global Trends" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical...
Stay up to date with the CNBC Stock Blog. Options Boil on Biotech Buyout Rumors Published: Thursday, 12 Nov 2009 | 3:42 PM ET By: David Russell writer, OptionMonster Cubist Pharmaceuticals is rebounding from a three-month low,...
Today's tickers: CBST, VIX, FSLR, HMY and M Cubist Pharmaceuticals ( CBST - news - people ): Some traders expect shares of the biopharmaceutical company to appreciate by expiration next Friday. Cubist now trades...
Kineta, the Seattle-based developer of drugs for autoimmune diseases, has won about half of a $13 million federal contract awarded to the University of Washington to create new compounds which might be used to boost the...
LEXINGTON, Mass.----Cubist Pharmaceuticals, Inc. today announced that it has been named one of the Top Places to Work in Massachusetts in the second annual employee-based survey from The Boston Globe.
Two large development proposals that could boost Lexington’s growing reputation as a home for biotechnology are about to come up for a vote. In separate proposals, Lexington Technology Park developers Patriot Partners and...
’ stock dropped roughly 5 percent in afternoon trading Thursday on news the company’s year-on-year net loss more than tripled due to increased operating costs in the third quarter. The stock slide also was attributed to the...
Funding Will Accelerate Growth at Enterprise Social Software Startup REDWOOD CITY, Calif., November 4, 2009-- CubeTree, a freemium enterprise collaboration suite built on a social networking platform, today announced that it...
Request a Trial to NEW EDGAR Online Pro Form 8-K for ALNYLAM PHARMACEUTICALS, INC. Entry into a Material Definitive Agreement, Results of Operations a Item 1.01 Entry Into a Material Definitive Agreement. Roche Alliance In July...
CAMBRIDGE, Mass. - RNA drug developer Alnylam Pharmaceuticals Inc. reported a deeper third-quarter loss on Wednesday, primarily due to increased spending on stock based compensation and legal costs. The biopharmaceutical...
